- Home
- EVV vs PVLA Comparison
EVV vs PVLA Comparison
Compare EVV & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVV | PVLA |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVV | PVLA |
|---|---|---|
| Price | $9.93 | $82.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $145.24 |
| AVG Volume (30 Days) | ★ 323.7K | 243.4K |
| Earning Date | 01-01-0001 | 11-11-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $14.60 |
| 52 Week High | $10.07 | $114.69 |
Technical Indicators
Market Signals| Indicator | EVV | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 41.52 |
| Support Level | $9.88 | $74.40 |
| Resistance Level | $9.93 | $83.47 |
| Average True Range (ATR) | 0.04 | 5.91 |
| MACD | 0.00 | -1.09 |
| Stochastic Oscillator | 57.05 | 27.30 |
Price Performance
Historical ComparisonAbout EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.